Alyeska Investment Group L.P. Acquires New Holdings in Oculis Holding AG $OCS

Key Points

• Alyeska Investment Group L.P. has acquired 131,332 shares of Oculis Holding AG, valued at approximately $2.5 million, representing a 0.30% ownership stake in the company.
• Institutional investors currently hold 22.30% of Oculis, with notable increases in holdings from entities like Bank of America and Pivotal bioVenture Partners in recent quarters.
• Analysts maintain a positive outlook on Oculis, with an average rating of "Buy" and a target price of $35.75 following recent upgrades, including recommendations from Needham & Company and Chardan Capital.

Alyeska Investment Group L.P. purchased a new stake in shares of Oculis Holding AG (NASDAQ:OCS - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 131,332 shares of the company's stock, valued at approximately $2,499,000. Alyeska Investment Group L.P. owned approximately 0.30% of Oculis at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Bank of America Corp DE increased its stake in shares of Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after buying an additional 10,667 shares in the last quarter. Citadel Advisors LLC bought a new stake in Oculis during the 4th quarter worth about $389,000. Kestra Private Wealth Services LLC acquired a new stake in Oculis in the 1st quarter valued at about $234,000. Aberdeen Group plc raised its stake in shares of Oculis by 24.1% in the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company's stock worth $23,847,000 after acquiring an additional 243,695 shares during the last quarter. Finally, SR One Capital Management LP acquired a new position in shares of Oculis during the first quarter worth approximately $6,137,000. Institutional investors and hedge funds own 22.30% of the company's stock.

Oculis Trading Down 0.3%

NASDAQ:OCS traded down $0.05 during mid-day trading on Wednesday, hitting $17.14. The company had a trading volume of 13,866 shares, compared to its average volume of 42,411. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.55 and a current ratio of 4.55. Oculis Holding AG has a fifty-two week low of $11.78 and a fifty-two week high of $23.08. The firm has a market cap of $748.33 million, a P/E ratio of -6.42 and a beta of 0.26. The business's fifty day moving average is $17.77 and its two-hundred day moving average is $18.30.

Oculis (NASDAQ:OCS - Get Free Report) last announced its quarterly earnings results on Thursday, August 21st. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06). The company had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.14 million. Oculis had a negative net margin of 13,958.12% and a negative return on equity of 90.31%. As a group, research analysts expect that Oculis Holding AG will post -2.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on OCS shares. HC Wainwright raised their price target on shares of Oculis from $32.00 to $33.00 and gave the company a "buy" rating in a report on Friday, August 22nd. Needham & Company LLC started coverage on Oculis in a research report on Wednesday, August 27th. They issued a "buy" rating and a $36.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $35.75.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.